ESMO Compliant
Evidence Based
Estrogen Receptor
Positive (95%)
HER2 Status
Pertuzumab + Trastuzumab + Docetaxel
We transform unstructured clinical notes into structured biomarker profiles ready for analysis.
Our engine maps patient data against international standards (ESMO, NCCN) without 'black-box' hallucinations.
Visualize the entire treatment pathway, from neoadjuvant therapy to surgery and adjuvant systemic treatment.
Digitizing ESMO Guidelines into actionable Decision Trees. Traceable, transparent, and clinically valid patient journeys.
Decision Tree
Biomarkers
Guidelines
ER+ / PR+ / HER2- / Ki67 45%
Matched criteria for 'Luminal B-like (HER2-negative)'
Recommended: Endocrine therapy + CDK4/6 inhibitor
ESMO Guidelines
Early Breast CancerNCCN Database
Cross-reference checkOur Decision Tree technology is disease-agnostic. We are starting with Breast Cancer, but the infrastructure is built to scale across the entire medical spectrum.
Full implementation of ESMO guidelines for invasive and in-situ carcinoma.
Scaling the engine to cover high-incidence cancers with complex protocols.
Deploying MedHub Core to other chronic diseases requiring algorithmic care.